Decisions 2nd October 2012

At the meeting on 2nd October 2012 the following additions/changes to the formulary were agreed:



  • Approved, TLS Red for patients who have suffered a relapse of C. difficile infection, or for those patients with a first C. difficile infection who are taking concurrent antibiotics which they cannot stop.



  • Approved for use at NBT in addition to UHB, TLS Red for the treatment of hypercalcaemia in primary hyperparathyroidism.



  • Approved for use at NBT in addition to UHB, TLS Red.  A surgical glue.



  • Approved for the treatment of melasma, TLS Red, for Consultant Dermatologoist use only. 


Mesalazine - Octasa®

  • Approved, as our first line Mesalazine brand for new uncomoplicated patients (400mg and 800mg tablets), TLS Green.  Mezevant ® XL and Mesren® to be removed from formulary


Perampanel - Fycompa®

  • Approved for the adjunctive treatment in the management of partial onset seizures with or without secondary generalisation, TLS Red


Amantadine in MS

  • Approved for the use in MS patients with fatigue, TLS amber.


Tobramycin (TOBI Podhaler)

  • Deferred until results of contract price negotiation on nebulised tobramycin is known



  • Approved as the recommended choice for the treatment of heparin induced thrombocytopenina, TLS Red.  Danaparoid is now an alternative and Lepirudin removed.


Ulipristal - Esmya®

  • Approved for the treatment of uterine firboids, TLS Red


New/updated Shared Care Protocols


  • Disease Modifying Antirheumatic drugs - Azathioprine, Leflunomide, Methotrexate, Sodium aurothiomalate, Penicillamine, Hydroxychloroquine.  All updated.
  • Acamprosate
  • Valproic acid
  • Colistimethate for the use in chronic respiratory patients (adult non-Cystic Fibrosis)
  • Hepatitis B vaccination in renal patients
  • Stalevo
  • Ropinirole
  • Lanthanum
  • Naltrexone for alcohol withdrawl (TLS Change from Red to amber)
  • Naltrexone for opioid withdrawl


Other decisions/changes


  • Tafluprost added (for patients who need preservative free eye drops in the treatment of glaucoma)
  • Ivabradine - license extension for use in patients with heart failure

Last updated by: on 25-06-2014 22:48